Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.

Journal of medical virology - 1 May 2018

Ohya Kazuki, Akuta Norio, Suzuki Fumitaka, Fujiyama Shunichiro, Kawamura Yusuke, Kominami Yoko, Sezaki Hitomi, Hosaka Tetsuya, Kobayashi Masahiro, Kobayashi Mariko, Suzuki Yoshiyuki, Saitoh Satoshi, Arase Yasuji, Ikeda Kenji, Kumada Hiromitsu

Abstract excerpt

While the combination therapy of ribavirin (RBV) and sofosbuvir (SOF) is effective in genotype 2 HCV infection, the predictors of treatment efficacy and posttreatment changes in α-fetoprotein (AFP) and liver stiffness (markers of hepatocellular carcinoma), remain unclear. In this study, 302 patients with chronic HCV genotype 2 infection were treated with SOF (400 mg) plus RBV (400-1000 mg; based on body weight)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Fetoproteins
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Ribavirin

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Identifiers

PMID: 29315652
DOI: 10.1002/jmv.25023

Genes

AFP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.PMID 29315652Read ↗

Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.Semantic proximity Read ↗

Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.Semantic proximity Read ↗

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes.Semantic proximity Read ↗

Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype.Semantic proximity Read ↗

Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.Semantic proximity Read ↗

Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.Semantic proximity Read ↗

Clinical Predictors of Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection From Children to Adults.Semantic proximity Read ↗

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.Semantic proximity Read ↗

Hepatitis B: liver fibrosis and hepatocellular carcinoma.Semantic proximity Read ↗

α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.Semantic proximity Read ↗

Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.Semantic proximity Read ↗

Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.